4594 logo

BrightPath Biotherapeutics
4594

Last Price

Financial Snapshot

gainify

Market Data

Market Cap
¥7.57B
EV
¥6.32B
Shares Outstanding
112.97M
Beta
1.64
Industry
Biotechnology

Wall Street View

Analyst Rating
-
Analyst Target Price
-
Number of Analysts
0
P/E E
-
P/Revenue E
-

Historical 3Y Growth Rate

Revenue
-
EPS
-
Operating Cash Flow
-
Free Cash Flow
-

Forecasted 3Y Growth Rate

Revenue
-
EPS
-
Operating Cash Flow
-
Free Cash Flow
-

Margins & Returns

Gross Margin E
-
Net Profit Margin E
-
ROE E
-
ROCE
-

Dividends

DPS E
-
Payout Ratio E
-
Div. Yield E
-
DPS Last 3Y CAGR
-

Price Dynamic

Price

%

1M

3M

6M

1Y

3Y

5Y

Peers

gainify

About BrightPath Biotherapeutics Co., Ltd.

gainify
4594 logo

BrightPath Biotherapeutics Co., Ltd.

4594

BrightPath Biotherapeutics Co., Ltd. engages in the development of cancer immunotherapy drugs in Japan. It is developing GRN-1201, a cancer peptide vaccine candidate that is in Phase II clinical trials for the treatment of non-small cell lung cancer, as well as in Pha...

Sector

Healthcare

Industry

Biotechnology

CEO

Nagai, Kenichi

Employees

42

IPO Date

2015-10-22

Headquarters

Kojimachi Central Building, 7th Floor, 2-2-4 Kojimachi, Chiyoda-ku, Tokyo Japan

📊 Stock Price & Performance

The last closing price of BrightPath Biotherapeutics (4594) is ¥67.00, reflecting a +0.00% change from the prior session. Last updated: February 15, 2026 at 9:31 PM Eastern Time

Review of Recent 4594 Stock Performance trends:Past 1 Month: BrightPath Biotherapeutics (4594) shares changed by +21.82%.Past 3 Months: The stock recorded a change of +11.67%.Past 6 Months: 4594 shares posted a change of -29.47%. Last updated: February 15, 2026 at 5:52 PM Eastern Time

Over the last year, BrightPath Biotherapeutics (4594) has established a 52-week price range between a high of ¥114.00 and a low of ¥32.00. This metric is essential for assessing the stock's annual volatility. Last updated: February 15, 2026 at 5:52 PM Eastern Time

BrightPath Biotherapeutics (4594) is considered a high volatility stock. It has a beta of 1.64, which means it typically moves 1.64 times as much as the broader market. Over the past 52 weeks, 4594 has traded within a ¥32.00 – ¥114.00 range. Last updated: February 15, 2026 at 5:52 PM Eastern Time

A ¥1,000 investment in BrightPath Biotherapeutics 5 years ago, when the stock was trading around ¥201.05, would be worth approximately ¥333.25 today, based solely on share price performance (excluding dividends). This represents a total return of -66.68% over the period, equivalent to a compound annual growth rate (CAGR) of -19.73%. Past performance reflects historical price movements only and does not imply future results. Last updated: February 15, 2026 at 5:52 PM Eastern Time

💰 Financial Metrics & Reports

The current BrightPath Biotherapeutics (4594) market capitalization is approximately ¥7.57B, based on its latest share price and shares outstanding. Market capitalization represents the total market value of a company's equity and is calculated by multiplying the current stock price by the number of shares outstanding. As a result, BrightPath Biotherapeutics's market cap fluctuates with changes in its share price and share count. Last updated: February 15, 2026 at 5:52 PM Eastern Time

📅 Earnings & Dividends

BrightPath Biotherapeutics (4594) does not currently pay a dividend. Over the last twelve months (LTM), the company paid ¥0.00 per share in dividends, and no dividend payments are currently expected over the next twelve months (NTM). Companies that do not pay dividends typically prioritize reinvesting cash into growth initiatives, capital expenditures, debt reduction, or strategic investments, though dividend policy may change in the future.

📈 Analyst Information

Based on the latest available analyst coverage, BrightPath Biotherapeutics (4594) currently carries a not available consensus rating. Analyst views are forward-looking estimates and should not be considered investment advice. Last updated: February 15, 2026 at 9:31 PM Eastern Time

Like other publicly traded stocks, BrightPath Biotherapeutics (4594) shares are bought and sold on stock exchanges such as TSE and other supported markets, depending on the listing. The most common way to buy shares is through an online brokerage account. To get started, you typically need to: Open an account with a licensed stock brokerComplete the broker's verification processFund your accountPlace a buy order for BrightPath Biotherapeutics (4594) shares Trading involves risk, and investors should consider their financial objectives and risk tolerance before investing.

ℹ️ Company Information

At the top right of this page, you'll see a star icon labeled Add to watchlist. Click it to add 4594 to your watchlist.

BrightPath Biotherapeutics trades under the ticker symbol 4594 on the TSE stock exchange. The ticker 4594 is used to identify the company's common stock across trading platforms, market data providers, and regulatory filings.

As of the most recently reported period, BrightPath Biotherapeutics (4594) employs approximately 42 people worldwide. Reported employee figures may fluctuate over time due to hiring activity, restructuring, automation initiatives, or changes in business strategy. Headcount data is typically disclosed in company filings and reflects full-time employees unless otherwise stated. Last updated: February 15, 2026 at 5:52 PM Eastern Time

BrightPath Biotherapeutics (4594) operates in a highly competitive market with companies that often have different business models, geographic exposure, and end markets. While no two companies are identical, the following firms are generally considered the closest BrightPath Biotherapeutics (4594) stock peers based on overlapping products, services, and competitive dynamics:Alaunos Therapeutics (TCRT)TYK Medicines (2410)Sunho Biologics (2898)Zelluna (ZLNA)vTv Therapeutics (VTVT)Adagene (ADAG)Laekna (2105)Nano Holdings (4571)Solasia Pharma K.K. (4597)Jiangsu Recbio Technology (2179) These peers may differ in size, business mix, financial profile, and strategic focus, but they are commonly referenced due to overlapping markets, customer segments, or competitive positioning relative to BrightPath Biotherapeutics.

gainifypowered-by-sp
Socials
Send us an emailFollow us on XConnect with us on LinkedInFollow us on InstagramFollow us on ThreadsCheck us out on TrustpilotFollow us on YouTubeFind us on Google Maps

Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2026, S&P Global Market Intelligence. All rights reserved.

View Data Providers

NEWSLETTER

Gainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.

© 2026 Gainify. All rights reserved.